Raymond James Financial Inc. Invests $583,000 in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Raymond James Financial Inc. acquired a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the 4th quarter, Holdings Channel.com reports. The firm acquired 108,989 shares of the company’s stock, valued at approximately $583,000.

A number of other institutional investors also recently bought and sold shares of CRVS. Geode Capital Management LLC raised its stake in Corvus Pharmaceuticals by 22.4% during the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock worth $2,974,000 after acquiring an additional 102,869 shares during the period. State Street Corp raised its position in shares of Corvus Pharmaceuticals by 48.2% during the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock valued at $941,000 after purchasing an additional 57,943 shares during the period. Jane Street Group LLC bought a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter valued at $265,000. JPMorgan Chase & Co. lifted its stake in shares of Corvus Pharmaceuticals by 441.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 49,556 shares of the company’s stock valued at $262,000 after buying an additional 40,404 shares in the last quarter. Finally, Masso Torrence Wealth Management Inc. boosted its holdings in Corvus Pharmaceuticals by 200.0% in the 4th quarter. Masso Torrence Wealth Management Inc. now owns 30,000 shares of the company’s stock worth $160,000 after buying an additional 20,000 shares during the period. 46.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. Oppenheimer reissued an “outperform” rating and set a $15.00 target price (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.67.

Corvus Pharmaceuticals Stock Performance

Shares of NASDAQ CRVS opened at $2.85 on Monday. The firm’s fifty day moving average is $4.39 and its two-hundred day moving average is $5.99. Corvus Pharmaceuticals, Inc. has a 52-week low of $1.30 and a 52-week high of $10.00. The company has a market cap of $194.19 million, a P/E ratio of -3.06 and a beta of 0.91.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its earnings results on Tuesday, March 25th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06). As a group, analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current fiscal year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.